Silexion Therapeutics Corp (SLXN) stock
SLXNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SLXNW
$1.44−0.21 (-12.73%)
Close on Nov 18, 2026Market cap $868.40KP/E –Yield –
Silexion Therapeutics cash
Cash and short-term investments held at the end of each period.
Silexion Therapeutics's cash was $4.76M at Sep 30, 2026. For fiscal 2025 it was $5.99M, up 371.7% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.99M | +371.7% |
| FY2024 | Dec 31, 2024 | $1.27M | -72.7% |
| FY2023 | Dec 31, 2023 | $4.65M | -44.1% |
| FY2022 | Dec 31, 2022 | $8.31M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.76M | -48.9% |
| Q2 FY2026 | Jun 30, 2026 | $2.32M | -34.5% |
| Q1 FY2026 | Mar 31, 2026 | $2.50M | -59.9% |
| Q4 FY2025 | Dec 31, 2025 | $5.99M | +371.7% |
| Q3 FY2025 | Sep 30, 2025 | $9.32M | +360.9% |
| Q2 FY2025 | Jun 30, 2025 | $3.54M | +102.9% |
| Q1 FY2025 | Mar 31, 2025 | $6.23M | +120.2% |
| Q4 FY2024 | Dec 31, 2024 | $1.27M | -72.7% |
| Q3 FY2024 | Sep 30, 2024 | $2.02M | -65.2% |
| Q2 FY2024 | Jun 30, 2024 | $1.75M | -73.1% |
| Q1 FY2024 | Mar 31, 2024 | $2.83M | -64.3% |
| Q4 FY2023 | Dec 31, 2023 | $4.65M | -44.1% |
| Q3 FY2023 | Sep 30, 2023 | $5.81M | – |
| Q2 FY2023 | Jun 30, 2023 | $6.49M | – |
| Q1 FY2023 | Mar 31, 2023 | $7.92M | – |
| Q4 FY2022 | Dec 31, 2022 | $8.31M | – |
See a number that looks wrong?